Holen Sie sich die Stockscreener-App
0.0127
3.05%
-0.0004
Handel nachbörslich:
.01
-0.0027
-21.26%
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Why Is Vincerx Pharma, Inc. (VINCU) Stock Down Today? - Meyka
Drug Transport Company Sued by Insurer Over Destroyed-Cells Case - Bloomberg Law News
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) - Defense World
Critical Review: Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN) - Defense World
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Vincerx Pharma (NASDAQ:VINC) & Petros Pharmaceuticals (NASDAQ:PTPI) - Defense World
Head to Head Analysis: Vectura Group (OTCMKTS:VEGPF) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx Pharma | DEFA14A: Others - Moomoo
Global Digital Holdings Inc. cancelled the acquisition of Vincerx Pharma, Inc. in a reverse merger transaction. - marketscreener.com
VINC: Vincerx Pharma to dissolve, with minimal or no distributions expected for stockholders - TradingView
VINC Stock Price, News & Analysis - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com Australia
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
vincerx pharma cancels merger, initiates wind-down activities By Investing.com - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx prepares to wind down as final merger attempt collapses - Fierce Biotech
Financially struggling drugmaker's potential rescue falls apart. It now will wind down - The Business Journals
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Yahoo Finance
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders - Finansavisen
Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Asianet Newsable
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Pharma (NASDAQ: VINCU)Share Price - intelligentinvestor.com.au
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants By Investing.com - Investing.com India
Vincerx Blames Stock Plunge On Overheated ADC Expectations - Citeline News & Insights
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx Pharma Presents Positive Preliminary Phase 1 Data - GlobeNewswire
Vincerx to Host Virtual Investor Event Reviewing - GlobeNewswire
Vincerx To Report VIP236 Trial Data Next Month - RTTNews
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? By Benzinga - Investing.com UK
Vincerx Pharma Announces Compelling Clinical Efficacy of - GlobeNewswire
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Ruth E. Stevens Net Worth (2026) - GuruFocus
Vincerx Pharma, Inc. (VINC) Dividend History, Date, and Yield - CoinCodex
Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD - Bioprocess Online
John C. Byrd Net Worth (2026) - gurufocus.com
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vincerx Pharma discovers new drug conjugates based on prodrugs of CDK9 inhibitors - BioWorld News
Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Vincerx Pharma, Inc. (VINC) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Vincerx Pharma Announces Poster Presentations at the - GlobeNewswire
Xiaoming Zhang Net Worth (2026) - GuruFocus
David Efraim Rosen Net Worth (2026) - GuruFocus
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference - GlobeNewswire
Vincerx Pharma Provides American Society of Hematology - GlobeNewswire
What is the current Price Target and Forecast for Vincerx Pharma (VINC) - Zacks Investment Research
0.74%
1.44%
Kapitalisierung:
|
Volumen (24h):